Organic crystallization processes

In the pharmaceutical industry, the issue of better control, desirable in and of itself, is reinforced by the need to satisfy both company internal and governmental regulatory authorities on the consistency of chemical and physical properties of active pharmaceutical ingredients (APIs). Control of crystallization operations and choice of equipment both for pilot plant and manufacturing are thereby critical. The objective of this paper is to summarize the critical issues that must be addressed in order to achieve this level of control.